BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2771990)

  • 1. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
    [No Abstract]   [Full Text] [Related]  

  • 3. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y; Akaza H; Kameyama S; Niijima T
    Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
    [No Abstract]   [Full Text] [Related]  

  • 5. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E; Jauhiainen K; Alfthan O
    Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].
    Steg A; Leleu C; Boccon-Gibod L; Debré B
    Ann Urol (Paris); 1986; 20(1):26-32. PubMed ID: 3707074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
    Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
    Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intravesical instillations of BCG and bladder carcinoma in situ].
    Haab F; Dauge MC; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):988-94; discussion 992-3. PubMed ID: 8305942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathological effects of intravesical BCG therapy.
    Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
    Prog Clin Biol Res; 1989; 310():93-105. PubMed ID: 2672025
    [No Abstract]   [Full Text] [Related]  

  • 12. [Topical BCG therapy of in situ cancer of the urinary bladder].
    Mack D; Jakse G
    Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
    Okuno H; Shirahase T; Kihara Y; Arai Y
    Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical BCG vaccine in bladder cancer].
    Beisland HO; Sander S
    Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of carcinoma in situ of the urinary bladder with BCG].
    Schnyder von Wartensee M; Ackermann D; Studer UE; Zingg EJ
    Helv Chir Acta; 1989 Aug; 56(3):351-4. PubMed ID: 2807965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [T1 G3 bladder tumors: the respective role of BCG and cystectomy].
    Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H
    Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-dose BCG in the therapy of superficial neoplasms of the bladder].
    Francesco Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A; Aragona F; Tejerizo JC; Pagano F
    Arch Esp Urol; 1990 Jun; 43(5):503-7. PubMed ID: 2202264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.